Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Raltegravir, in combination with other anti-HIV medicines, maintained reductions in HIV-1 viral load and increased CD4 cell counts through 48 weeks of therapy in treatment-experienced adults

Merck Sharp & Dohme Limited
Posted on: 07 Feb 08

For more information:

Editor's Details

Natalie Lewis
020 7031 4403

Last updated on: 27/08/2010

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.